253 related articles for article (PubMed ID: 20703488)
1. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
Wollenhaupt J; Krüger K
Z Rheumatol; 2010 Sep; 69(7):618-25. PubMed ID: 20703488
[TBL] [Abstract][Full Text] [Related]
2. Newer biological agents in the treatment of rheumatoid arthritis: do the benefits outweigh the risks?
Nurmohamed MT
Drugs; 2009 Oct; 69(15):2035-43. PubMed ID: 19791825
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapy in rheumatoid arthritis.
Köller MD
Wien Med Wochenschr; 2006 Jan; 156(1-2):53-60. PubMed ID: 16465614
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
5. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis.
Papagoras C; Voulgari PV; Drosos AA
Autoimmun Rev; 2010 Jun; 9(8):574-82. PubMed ID: 20433955
[TBL] [Abstract][Full Text] [Related]
6. The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drug.
Navarro Coy NC; Brown S; Bosworth A; Davies CT; Emery P; Everett CC; Fernandez C; Gray JC; Hartley S; Hulme C; Keenan AM; McCabe C; Redmond A; Reynolds C; Scott D; Sharples LD; Pavitt S; Buch MH
BMC Musculoskelet Disord; 2014 Dec; 15():452. PubMed ID: 25539805
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and tolerability of newer biologics in rheumatoid arthritis: best current evidence.
Siddiqui MA
Curr Opin Rheumatol; 2007 May; 19(3):308-13. PubMed ID: 17414961
[TBL] [Abstract][Full Text] [Related]
8. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
Furst DE; Breedveld FC; Kalden JR; Smolen JS; Burmester GR; Sieper J; Emery P; Keystone EC; Schiff MH; Mease P; van Riel PL; Fleischmann R; Weisman MH; Weinblatt ME
Ann Rheum Dis; 2007 Nov; 66 Suppl 3(Suppl 3):iii2-22. PubMed ID: 17934088
[No Abstract] [Full Text] [Related]
9. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists.
Isaacs JD
Expert Opin Biol Ther; 2009 Dec; 9(12):1463-75. PubMed ID: 19916731
[TBL] [Abstract][Full Text] [Related]
10. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
Swierkot J; Madej M
Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177
[TBL] [Abstract][Full Text] [Related]
11. Biological therapy for rheumatoid arthritis: where are we now?
Horton SC; Emery P
Br J Hosp Med (Lond); 2012 Jan; 73(1):12-8. PubMed ID: 22241404
[TBL] [Abstract][Full Text] [Related]
12. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies.
Favalli EG; Biggioggero M; Marchesoni A; Meroni PL
Rheumatology (Oxford); 2014 Sep; 53(9):1664-8. PubMed ID: 24729445
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of tocilizumab, rituximab, abatacept and tofacitinib in patients with active rheumatoid arthritis that inadequately responds to tumor necrosis factor inhibitors: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Bae SC
Int J Rheum Dis; 2016 Nov; 19(11):1103-1111. PubMed ID: 26692536
[TBL] [Abstract][Full Text] [Related]
14. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.
Crnkic Kapetanovic M; Saxne T; Jönsson G; Truedsson L; Geborek P
Arthritis Res Ther; 2013 Oct; 15(5):R171. PubMed ID: 24286269
[TBL] [Abstract][Full Text] [Related]
15. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.
Daïen CI; Morel J
Mediators Inflamm; 2014; 2014():386148. PubMed ID: 24523570
[TBL] [Abstract][Full Text] [Related]
16. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
Gibbons LJ; Hyrich KL
BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
[TBL] [Abstract][Full Text] [Related]
17. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010.
Furst DE; Keystone EC; Braun J; Breedveld FC; Burmester GR; De Benedetti F; Dörner T; Emery P; Fleischmann R; Gibofsky A; Kalden JR; Kavanaugh A; Kirkham B; Mease P; Sieper J; Singer NG; Smolen JS; Van Riel PL; Weisman MH; Winthrop K
Ann Rheum Dis; 2011 Mar; 70 Suppl 1():i2-36. PubMed ID: 21339216
[No Abstract] [Full Text] [Related]
18. New therapeutic options in rheumatoid arthritis: a focus on interleukin-6 blockade.
Furfaro N
J Infus Nurs; 2011; 34(2):107-15. PubMed ID: 21399456
[TBL] [Abstract][Full Text] [Related]
19. Abatacept or tocilizumab after rituximab in rheumatoid arthritis? An exploratory study suggests non-response to rituximab is associated with persistently high IL-6 and better clinical response to IL-6 blocking therapy.
Das S; Vital EM; Horton S; Bryer D; El-Sherbiny Y; Rawstron AC; Ponchel F; Emery P; Buch MH
Ann Rheum Dis; 2014 May; 73(5):909-12. PubMed ID: 24385201
[TBL] [Abstract][Full Text] [Related]
20. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review.
Rubbert-Roth A; Finckh A
Arthritis Res Ther; 2009; 11 Suppl 1(Suppl 1):S1. PubMed ID: 19368701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]